Skip to content

Dr. Parravano Mariacristina

Head of the Research Unit
Researcher
Fondazione Bietti_Parravano Mariacristina
Linea di ricerca: Medical and surgical retina
Unità di ricerca: UR Medical Retina
Unità Operativa Semplice: Simple Operating Unit Medical Retina, low vision and visual rehabilitation 
Principali specializzazioni: DIABETIC RETINOPATHY, AGE-RELATED MACULAR DEGENERATION (AMD), REFRACTIVE ERRORS, LOW VISION AND VISUAL REHABILITATION, RETINAL VEIN OCCLUSION, MACULAR PATHOLOGY OF SURGICAL INTEREST, RETINAL DETACHMENT

Medical activity: UOC Ophthalmology G.B.Bietti-IRCCS Foundation at British Hospital, San Giovanni Addolorata Hospital Complex in Rome and Clinical Trial Center G.B.Bietti-IRCCS Foundation Via Livenza n 3 in Rome

Scientific publication: PubMed

linkedin: Mariacristina Parravano

E-Mail: mariacristina.parravano@fondazionebietti.it

2004

Diploma of specialist in Ophthalmology

 

2001-2004

Residency in Ophthalmology at the University of Rome “Tor Vergata” Medical School.

 

2000

Degree in Medicine and Surgery with score of 110/110 and lode at the University Campus BioMedico

of Rome.

 

1995

High school diploma with a score of 58/60 from “Liceo Classico V.Simoncelli” Sora, FR

April 2017            Associate Professor in Ophthalmology

 

From 2015          Head of Medical Retina Unit in IRCCS-Fondazione G.B.Bietti

2004-2017          Researcher in the Medical Retina Unit IRCCS-Fondazione G.B.Bietti

 

2008-2017          Consultant in the Maculopathy Center in ASL Complesso Ospedaliero S.Giovanni

Addolorata, IRCCS-Fondazione G.B.Bietti

April 2017            Associate Professor in Ophthalmology

From 2015          Head of Medical Retina Unit in IRCCS-Fondazione G.B.Bietti

  • Safety and Efficacy of Abicipar Pegol in Patients with Neovascular Age-related Macular Degeneration (DARPin) Allergan. Principal Investigator.

 

  • A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY OF EFFICACY AND SAFETY OF 10 mg LAMPALIZUMAB INTRAVITREAL INJECTIONS ADMINISTERED EVERY 30 OR 45 DAYS TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION. ROCHE. Principal Investigator

-Acta Ophthalmologica

-Plosone

-IOVS

-BJO

-Acta Diabetologica

-Cochrane systemic revision

-Ophthalmologica

-AJO

-Retina

-AJO

Italian Review of Ophthalmology

Ophthalmology@Point of Care

Winner 2003 ARVO Travel Grant Fondazione GB Bietti per lo studio e la ricerca in Oftalmologia.

Winner 2009 clinical research “Associazione Amici di Vanda” during Givre Meeting, Varese 19 June 2009.

Winner Conto Capitale 2015 Ministry of Health ” Multimodal morpho-functional wide-field analysis for the neuro-vascular study of neuro-retinal pathologies with high social impact “

Skip to content